ATE267582T1 - Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen - Google Patents

Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen

Info

Publication number
ATE267582T1
ATE267582T1 AT01909587T AT01909587T ATE267582T1 AT E267582 T1 ATE267582 T1 AT E267582T1 AT 01909587 T AT01909587 T AT 01909587T AT 01909587 T AT01909587 T AT 01909587T AT E267582 T1 ATE267582 T1 AT E267582T1
Authority
AT
Austria
Prior art keywords
administerable
nasal
peptide compositions
antifungal peptide
cyclic
Prior art date
Application number
AT01909587T
Other languages
English (en)
Inventor
Ikuo Horii
Kazuko Kobayashi
Nobuo Shimma
Akira Yanagawa
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Application granted granted Critical
Publication of ATE267582T1 publication Critical patent/ATE267582T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT01909587T 2000-01-20 2001-01-09 Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen ATE267582T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00101057 2000-01-20
PCT/EP2001/000163 WO2001052894A2 (en) 2000-01-20 2001-01-09 Nasally administrable cyclic peptide compositions

Publications (1)

Publication Number Publication Date
ATE267582T1 true ATE267582T1 (de) 2004-06-15

Family

ID=8167663

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909587T ATE267582T1 (de) 2000-01-20 2001-01-09 Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen

Country Status (16)

Country Link
US (1) US20010038824A1 (de)
EP (1) EP1251827B1 (de)
JP (1) JP2003535042A (de)
KR (1) KR20020070346A (de)
CN (1) CN1406124A (de)
AR (1) AR027244A1 (de)
AT (1) ATE267582T1 (de)
AU (1) AU3728001A (de)
BR (1) BR0107764A (de)
CA (1) CA2396381A1 (de)
DE (1) DE60103504T2 (de)
DK (1) DK1251827T3 (de)
ES (1) ES2220724T3 (de)
MX (1) MXPA02007052A (de)
WO (1) WO2001052894A2 (de)
ZA (1) ZA200205240B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254161B1 (de) * 2000-01-17 2005-04-20 Basilea Pharmaceutica AG Aerothricin analoge, deren herstellung und verwendung
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
KR20040058324A (ko) * 2001-11-26 2004-07-03 다이이찌 산토리 파마 가부시키가이샤 경비흡수용 의약 조성물
US7047259B1 (en) 2002-06-25 2006-05-16 Oracle International Corporation Rich cross object navigation in mobile applications
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
NZ541167A (en) * 2003-01-31 2008-07-31 Orexo Ab A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
WO2007134241A2 (en) * 2006-05-11 2007-11-22 University Of Maryland Baltimore Nasal delivery of therapeutic agents using tight junction agonists
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
CN101861311A (zh) 2007-07-21 2010-10-13 阿尔巴尼分子研究公司 5-吡啶酮取代的吲唑
JP2011504505A (ja) 2007-11-21 2011-02-10 デコード ジェネティクス イーエイチエフ 肺および心血管障害を治療するためのビアリールｐｄｅ４抑制剤
KR101614723B1 (ko) 2008-01-11 2016-04-22 알바니 몰레큘라 리써치, 인크. Ｍｃｈ 길항물질로서 (1-아지논)-치환된 피리도인돌
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
KR20150116466A (ko) 2009-01-26 2015-10-15 이스라엘 인스티튜트 포 바이올로지컬 리서치 이환형 헤테로사이클릭 스피로 화합물
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
ES2663335T3 (es) * 2010-03-19 2018-04-12 Daiichi Sankyo Company, Limited Composición para administración transnasal y método para prepararla
CN102746384B (zh) * 2011-04-22 2016-01-20 上海天伟生物制药有限公司 一种高纯度的卡泊芬净或其盐及其制备方法和用途
HRP20161703T1 (hr) 2012-11-20 2017-03-10 Fresenius Kabi Usa, Llc Formulacije kaspofungin acetata
JP2018529749A (ja) 2015-10-07 2018-10-11 シプルメット・ゲーエムベーハー ペプチド薬物を経口送達するための医薬製剤
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN112135613A (zh) 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
EP3846792A4 (de) 2018-09-06 2022-10-12 Innopharmascreen Inc. Verfahren und zusammensetzungen zur behandlung von asthma oder morbus parkinson
WO2020142485A1 (en) 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202126323A (zh) * 2019-10-01 2021-07-16 約翰斯赫普金斯大學 雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法
CN112852908B (zh) * 2021-01-11 2023-05-19 青海省农林科学院 一种具有除草作用的短梗霉素及其制备方法、测定方法
CN121358486A (zh) * 2023-06-30 2026-01-16 杭州先为达生物科技股份有限公司 具有提高药物口服生物利用度的组合物及其方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US5331089A (en) * 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
US5051400A (en) * 1990-06-28 1991-09-24 Smithkline Beecham Corporation Method of treating nausea and emesis related to motion sickness with vasopressin antagonists
AU657961B2 (en) * 1991-04-19 1995-03-30 Nexstar Pharmaceuticals, Inc. Pharmaceutical formulation and process
ZA936692B (en) * 1992-09-12 1994-04-29 Dott Ltd Comp Physiologically active peptide composition
FI92334C (fi) * 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
WO1996022784A1 (en) * 1995-01-26 1996-08-01 Merck & Co., Inc. Novel antifungal cyclohexapeptides
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
US5830855A (en) * 1996-09-12 1998-11-03 Utah State University Lipodepsipeptides as antifungal and fungicidal agents
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
MA26663A1 (fr) * 1998-07-23 2004-12-20 Hoffmann La Roche Nouvelles aerothricines et leurs applications antifongiques

Also Published As

Publication number Publication date
CN1406124A (zh) 2003-03-26
US20010038824A1 (en) 2001-11-08
ES2220724T3 (es) 2004-12-16
DK1251827T3 (da) 2004-09-27
WO2001052894A2 (en) 2001-07-26
ZA200205240B (en) 2003-09-29
EP1251827B1 (de) 2004-05-26
CA2396381A1 (en) 2001-07-26
BR0107764A (pt) 2002-11-12
AR027244A1 (es) 2003-03-19
EP1251827A2 (de) 2002-10-30
AU3728001A (en) 2001-07-31
JP2003535042A (ja) 2003-11-25
KR20020070346A (ko) 2002-09-05
MXPA02007052A (es) 2002-12-13
DE60103504T2 (de) 2005-06-09
WO2001052894A3 (en) 2002-01-31
DE60103504D1 (de) 2004-07-01

Similar Documents

Publication Publication Date Title
ATE267582T1 (de) Nasal verabreichbare cyclische antimykotische peptidzusammensetzungen
NO20030916L (no) Selektive cykliske peptider
NO20034925L (no) Cykliske N-aroylaminer
PL364773A1 (pl) Inhalator dozujący ksynafonian salmeterolu
DK1314437T3 (da) Stabiliserede antistofindeholdende præparater
NO20025450L (no) Ny farmasöytisk sammensetning
DE60128658D1 (de) Gefaltete sagnac-sensorgruppe
EP1402001A4 (de) Antimikrobielle peptide und zusammensetzungen
DE60118021D1 (de) Medizinische aerosolzusammensetzung
DE69911579D1 (de) Antimikrobielle peptide
DE60122873D1 (de) Therapeutische porenbildende peptide
DE60139339D1 (de) Stabilisierte interferonzusammensetzungen
NO20034556D0 (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
FR2813080B1 (fr) Peptides anti-heparine
ATE293126T1 (de) Cyclische hexapeptidderivate
EP1359932A4 (de) Tip39 polypeptide
NO20032963L (no) Peptidforbindelser
EP1359930A4 (de) Novispirine: antimikrobielle peptide
EP1159288A4 (de) Alpha-conotoxin-peptide
EP1246834A4 (de) Epididymale antimikrobielle peptide
GB0030309D0 (en) Antibodies,Peptides,Analogs and uses thereof
EP1385881A4 (de) Polypeptide mit anti-obesitas-wirkung
EP1312612A4 (de) Zyklisches peptid-derivat
FI20002159L (fi) Uudet peptidiligandit
EP1362865A4 (de) Cyclisches peptid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1251827

Country of ref document: EP

REN Ceased due to non-payment of the annual fee